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ABSTRACT Lipid-based nanocarriers or liposomes have
been proven successful in the delivery of chemotherapeutic
agents and are currently applied clinically in the treatment of
various types of cancer. Liposomes offer the advantage of a
high drug payload, decreased drug toxicity and enhanced drug
accumulation at tumor sites. Increased accumulation is due to
the relatively leaky tumor vasculature that allows liposome
extravasation. Between different types of tumors and even
within one tumor, vascular permeability and thus liposome
extravasation may differ greatly. Furthermore, upon accumula-
tion of liposomes in the tumor area, drug bioavailability is not
guaranteed. At present, these are the major issues for clinically
used liposomal drugs.
Mild hyperthermia (HT), the heating of tumor tissue to
temperatures of up to 43°C, has been developed in the past
decades as an established and efficacious treatment modality in
combination with chemo- and radiotherapy. HTcan be used to
further improve liposomal chemotherapy in two ways: HT is
known to increase vascular permeability in solid tumors and
may therefore increase levels of liposome accumulation, and
thermosensitive liposomes have been developed that can be
triggered to release their contents upon hyperthermia. By
applying these two strategies, drug delivery to tumors can be
strongly enhanced.
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LIPOSOMAL DRUG DELIVERY
In the past 40 years, liposomes, phospholipid-based nano-
vesicles, have been studied extensively as a drug delivery
system, for example for the treatment of tumors. They
currently represent one of the best studied types of drug
delivery systems and are being used clinically either as
experimental drug in various stages of clinical trials or as an
approved and established drug. Examples of the latter are
liposomal amphotericin B (Ambisome®) for fungal infec-
tions, liposomal daunorubicin (Daunoxome®), and pegy-
lated liposomal doxorubicin (PLD) (Doxil®/Caelyx®), both
for anticancer therapy. Liposomes have attractive charac-
teristics for use in drug delivery. Hydrophilic drugs can be
entrapped in the liposome’s aqueous compartments, while
the lipid bilayer can be utilized to incorporate hydrophobic
drugs. Associating a drug with liposomes will markedly
change its pharmacokinetic properties and lower its systemic
toxicity; furthermore, the drug is prevented from early
inactivation in circulation. A major advancement in the use
of liposomes was the development of small (∼ 100 nm) long-
circulating liposomes, which renders the carrier and thus its
drug contents with a long blood-residence time. These
favorable circulation properties result in an enhanced accu-
mulation of liposomal drugs in the tumor area (Fig. 1A)( 1).
Tumor sites are characterized by an immature leaky
vasculature due to angiogenesis. However, the increased
vascular permeability of tumor vasculature varies strongly
between different tumor types and even within a tumor as
was demonstrated in animal tumor models (2,3)a sw e l la si n
cancer patients (4).
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drugs that have been associated with liposomes. Liposomal
formulations of doxorubicin and daunorubicin are either
approved or under clinical investigation for treatment of
several types of cancer (5), e.g. Kaposi’s Sarcoma, ovarian
cancer, metastatic breast cancer, and multiple myeloma. A
major benefits of the liposomal anthracyclin delivery
compared to administration of the free drug is decreased
(cardio)toxicity, with remaining efficacy also in typically
anthracyclin-resistant tumors. However, in general, in all
these clinical trials, no strong increases in therapeutic
efficacy of liposomal doxorubicin have been described in
comparison to the free drug. A main reason for this is that
accumulation of liposomes in the tumor area does not
guarantee that the encapsulated drug becomes bioavailable
to the tumor cells. Not much is known about the actual fate
of liposomal doxorubicin upon extravasation in a tumor.
Seynhaeve et al. showed a significant level of uptake of
liposomal doxorubicin by tumor cells followed by slow
intracellular release, which ultimately renders the doxoru-
bicin bioavailable as evidenced by its nuclear localization
2–3 days after administration (3). Laghina et al. quantified
bioavailability of liposomal doxorubicin to be around 30 to
50% over several days after administration by measuring
total tumor drug levels in comparison to the actual
bioavailable drug levels measured in tumor cell nuclei (6).
Summarizing, results from clinical trials are promising
but also leave room for further improvement. At least two
main strategies are being recognized to this respect: 1)
increased and more homogeneous accumulation of liposo-
mal drugs in tumors and 2) increased bioavailability of the
drugs by triggered release from liposomes to tumor cells. It
is our strong belief that hyperthermia can be of great
importance to achieve success in both suggested strategies.
HYPERTHERMIA
Mild hyperthermia involves the heating of tumors to
temperatures of up to 43 degrees and is usually combined
with radiation or chemotherapy to enhance the therapeutic
outcome of these treatments.P r e s e n t l y ,h y p e r t h e r m i a
Fig. 1 Beneficial effects of hyperthermia on liposome extravasation and drug delivery to solid tumors. A. liposomes by virtue of their prolonged
circulation capacity and small size may extravasate from tumor vasculature, which is more permeable than normal vasculature. B. Hyperthermia is known
to increase vascular permeability, giving rise to increased levels of liposomes accumulating in the tumor tissue. C. In the interstitial drug release approach, a
heat trigger is applied to rapidly release drugs from tumor-localized thermosensitive liposomes in close proximity of tumor cells (represented by a red drug
gradient in the tumor tissue). Subsequently, the drug is mainly taken up by tumor cells after which it can reach its site of action, e.g. the nucleus. D. In the
intravascular release approach, thermosensitive liposomes reach the heated tumor area and immediately start releasing their drug contents intravascularly
(represented by a red drug gradient arising from the tumor blood vessel). Released drugs will be absorbed by the tumor tissue and can be taken up by
both tumor and endothelial cells.
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on the tumor by focusing electromagnetic or ultrasound
energy on the tumor area using, e.g., radiofrequency
electrodes implanted in the tumor or microwave antennas
and ultrasound transducers that apply their energy to the
tumor non-invasively.
Mild hyperthermia is known to cause major increases
in tumor perfusion, this being one main reason for its
synergistic effects with chemo and radiation treatment. In
radiation treatment, increased perfusion will increase
tumor oxygen levels and thereby the detrimental effects
of the applied radiation. Improved drug delivery relies
on the fact that local heating results in perforation of
tumor blood vessels, microconvection in the interstitium,
and perforation of the cancer cell membrane. Altogether,
this enhances delivery of drugs from the blood into
cancer cells with minimal thermal and mechanical
damages to the normal tissues. In addition, hyperthermia
can render tumor cells temporarily more sensitive to the
damaging effects of radiation or chemotherapeutics.
Another important effect of hyperthermia is DNA repair
inhibition.
Firm clinical proof of increased efficacy upon combining
hyperthermia with chemotherapy has been obtained in the
past 10 years from a randomized trial in bladder cancer (7),
a trial in cervical cancer (8) and, more recently, a large
randomized EORTC trial in high-grade soft tissue sarco-
mas. Results of the latter study by Issels et al. were presented
at the meeting of the European Cancer Organization 2009
in Berlin. In this study, the overall survival was strongly
increased in the group of patients that completed the
hyperthermia and chemotherapy treatment combination
protocol compared to the group of patients receiving
chemotherapy alone (9). Altogether, these data demonstrate
that hyperthermia, after many years of development, has
become an established treatment in cancer therapy with a
high potency of improving the outcome of chemotherapy in
various types of cancer.
HYPERTHERMIA TO IMPROVE LIPOSOMAL
CHEMOTHERAPY
One of the next questions to be investigated is whether
hyperthermia is able to increase the efficacy of liposo-
mal chemotherapy. At present, there seems to be
significant evidence in favor of such an approach. The
remainder of this article will deal with these clinically
relevant options.
In analogy to the successful combination of vasoactive
compounds such as tumor necrosis factor alpha and
liposomal chemotherapy to increase tumor drug levels and
anti tumor activity (3,10), hyperthermia can induce similar
effects. Since hyperthermia has a major impact on several
tumor pathophysiological parameters, including perfusion
and vascular permeability, favorable effects on liposome
extravasation in tumor areas, as represented schematically
in Fig. 1B, can be anticipated and have already been
demonstrated in some animal tumor models (11). The
application of heat to tumors in animals in principle can
involve similar technology as in humans, but is usually
applied in a more straightforward way, for instance by
submersing s.c. tumor-bearing extremities in a heating bath
(12). Intravital microscopic imaging is a tool often used to
visualize intratumoral fate of thermosensitive liposomes and
release of their content. For this approach, heating of tissues
placed in a dorsal skin-fold window chamber with
implanted tumors can be achieved by placing it in a heated
incubator (13), by using conductive heating for the whole
(metal) window chamber (14), or, more precisely, by using a
circular conductive heating ring designed for the window
chamber (15).
More detailed studies during and after hyperthermia
moving towards the involved vascular and cellular mecha-
nisms, the actual fate of the liposomes after extravasation
and the reproducibility of these effects in various animal
tumor models and ultimately in cancer patients, are
important items for the future.
THERMOSENSITIVE LIPOSOMES
Upon arrival in the tumor area, heat may also be applied
to trigger the release of liposomal drug contents (Fig. 1C).
To achieve this, thermosensitive liposomes are being
developed. The formulation of such liposomes is based
on pioneering work of Yatvin and Weinstein in the late
1970s (16), who described the use of liposomes composed
of phospholipids that undergo a gel-to-liquid crystalline
phase transition at temperatures of around 44°C, a process
which, in the absence of cholesterol in the membrane,
causes significant release of liposome-entrapped water-
soluble compounds.
From this basic formulation, thermosensitive liposomes
have been further developed, for instance, by providing them
with long-circulating properties using poly(ethylene glycol)
(12,15,17) or oligoglycerol-moieties (14) and by incorporating
additional lipid compounds that further enhance membrane
permeability at the phase transition temperature of the lipid
membrane, e.g. lysolipid (12) or oligoglycerol-PG (14).
Importantly, the lysolipid formulation developed by
Needham and Dewhirst’s groups at Duke (USA) underwent
further pharmaceutical development by the biopharma-
ceutical company Celsion and has now reached the clinical
testing phase and is marketed as Thermodox®. Two main
studies are currently being performed combining Thermo-
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carcinoma of the chest wall and Thermodox with radio-
frequency ablation in patients with primary or metastatic
liver cancer. Results of these trials have not been published
yet; however, they have already justified further clinical
phase III testing in liver cancer patients (information
obtained from the company’s website at www.celsion.com).
These promising developments prove the high potential
of combining hyperthermia with thermosensitive liposomes
for delivery of chemotherapy to solid tumors.
INTRAVASCULAR AND INTERSTITIAL DRUG
RELEASE APPROACHES
The lysolipid-based thermosensitive liposomes are injected
just prior to or during the hyperthermia treatment with
immediate release of their contents upon arrival in the
heated tumor area, which is different from using the above-
mentioned long-circulating liposomal carriers for chemo-
therapy delivery to solid tumors. This approach is referred
to as the intravascular drug release approach and skips the
liposomal extravasation step to get into close proximity of
the tumor cells (Fig. 1D). The released drug, currently
doxorubicin, has been shown to be delivered efficiently
from the tumor vasculature to the tumor cells as well as to
vascular endothelial cells (18). More studies need to be done
in order to establish the efficiency of this delivery process
and whether this holds true for other chemotherapeutic
drugs as well.
Besides the intravascular release approach, combinations
of thermosensitive liposomes and hyperthermia are being
developed that aim at interstitial release (Fig. 1C). In this
approach, a primary hyperthermia treatment is applied to
increase tumor vascular permeability, after which thermo-
sensitive liposomes are administered that can extravasate
into the tumor area. Exact and optimal requirements for
the first hyperthermia treatment are not known. Kong et al.
showed increasing levels of extravascular appearance of
liposomes with increasing temperatures from 39 to 42°C
applied for 60 min to a human ovarian carcinoma
xenograft tumor in mice (11). They also demonstrated that
the increased vascular permeability in this tumor model
lasted up to 4 h after treatment. Upon reaching optimal
liposome accumulation levels in the tumor, a second
hyperthermia treatment can be applied to trigger drug
release from the tumor-localized liposomes in very close
proximity of the tumor cells. Since drug release from
thermosensitive liposomes can occur very fast, with burst
release of up to 70% of content in several minutes to
maximal release within 1 h of hyperthermia (12,14,15), the
duration of the second heat trigger can be tailored
accordingly.
IMAGING-GUIDED DRUG DELIVERY
Complicated drug delivery approaches as described above
would certainly benefit from imaging guidance. Therefore,
major efforts are being undertaken to provide liposomes
with contrast agents to monitor tumor accumulation levels
and drug release (1). Regarding thermosensitive liposomes,
radionuclides and nuclear imaging can be used to image
tumor accumulation of liposomes, but not drug release.
Magnetic resonance imaging (MRI) to this respect has the
advantage of being able to detect both liposome accumu-
lation and drug release when a co-encapsulated MRI
contrast agent is released together with the drug (19,20).
In addition, MRI thermometry information on tumor
temperatures during hyperthermia is available online.
Imaging-guided drug delivery using thermosensitive liposo-
mal nanocarriers will ultimately help to further optimize
and personalize cancer treatment and to get detailed online
information on the applied treatment.
CONCLUSION
In conclusion, the combination of two separate develop-
ments in cancer therapy that have already been initiated in
the 1970s seem to have promising potential to contribute to
further improvement of cancer therapy. The use of
thermosensitive liposomes in combination with hyperther-
mia will help to further improve the delivery of chemo-
therapeutic drugs to solid tumors. The liposomes will retain
their drug while in circulation, thereby preventing normal
tissue exposure and related side effects. Upon arrival in the
tumor area, they will only on command release their
contents by the application of local hyperthermia, resulting
in drug becoming bioavailable in close proximity of the
target tumor cells. As a matter of fact, this approach is now
undergoing clinical evaluation, which is a major step
forward. Current and future developments in this area will
include imaging-guided drug delivery approaches in which
the whole treatment, including liposome accumulation,
triggered drug release and tumor temperatures, can be
monitored online. This will contribute to further improved
efficacy of this combination treatment for the individual
patient.
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